🚀 VC round data is live in beta, check it out!
SciBase Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for SciBase Holding and similar public comparables like RenovoRx, Sequana Medical, Baumer, Q-linea and more.
SciBase Holding Overview
About SciBase Holding
SciBase Holding AB is a medical technology company that develops devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. The company's products include Nevisense and Nevisense Go and to date, the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. The company operates in two segments, which include skin cancer and skin barrier assessment. The majority of the revenue is generated from skin cancer segment.
Founded
1998
HQ
Employees
28
Website
Sectors
Financials (LTM)
EV
$45M
SciBase Holding Financials
SciBase Holding reported last 12-month revenue of $5M and negative EBITDA of ($9M).
In the same LTM period, SciBase Holding generated ($9M) in EBITDA losses and had net loss of ($10M).
Revenue (LTM)
SciBase Holding P&L
In the most recent fiscal year, SciBase Holding reported revenue of $4M and EBITDA of ($9M).
SciBase Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5M | XXX | $4M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $3M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 67% | XXX | XXX | XXX |
| EBITDA | ($9M) | XXX | ($9M) | XXX | XXX | XXX |
| EBITDA Margin | (162%) | XXX | (199%) | XXX | XXX | XXX |
| EBIT Margin | (169%) | XXX | (205%) | XXX | XXX | XXX |
| Net Profit | ($10M) | XXX | ($10M) | XXX | XXX | XXX |
| Net Margin | (185%) | XXX | (215%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SciBase Holding Stock Performance
SciBase Holding has current market cap of $46M, and enterprise value of $45M.
Market Cap Evolution
SciBase Holding's stock price is $0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $45M | $46M | 0.3% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSciBase Holding Valuation Multiples
SciBase Holding trades at 8.5x EV/Revenue multiple, and (5.3x) EV/EBITDA.
EV / Revenue (LTM)
SciBase Holding Financial Valuation Multiples
As of April 20, 2026, SciBase Holding has market cap of $46M and EV of $45M.
Equity research analysts estimate SciBase Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SciBase Holding has a P/E ratio of (4.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $46M | XXX | $46M | XXX | XXX | XXX |
| EV (current) | $45M | XXX | $45M | XXX | XXX | XXX |
| EV/Revenue | 8.5x | XXX | 10.2x | XXX | XXX | XXX |
| EV/EBITDA | (5.3x) | XXX | (5.1x) | XXX | XXX | XXX |
| EV/EBIT | (5.1x) | XXX | (5.0x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 15.3x | XXX | XXX | XXX |
| P/E | (4.7x) | XXX | (4.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SciBase Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SciBase Holding Margins & Growth Rates
SciBase Holding's revenue in the last 12 month grew by 66%.
SciBase Holding's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.
SciBase Holding's rule of 40 is (33%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SciBase Holding's rule of X is 77% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
SciBase Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 66% | XXX | 73% | XXX | XXX | XXX |
| EBITDA Margin | (162%) | XXX | (199%) | XXX | XXX | XXX |
| EBITDA Growth | (16%) | XXX | (7%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (33%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 77% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 184% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 35% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 59% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 281% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SciBase Holding Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SciBase Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| RenovoRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Sequana Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Baumer | XXX | XXX | XXX | XXX | XXX | XXX |
| Q-linea | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SciBase Holding M&A Activity
SciBase Holding acquired XXX companies to date.
Last acquisition by SciBase Holding was on XXXXXXXX, XXXXX. SciBase Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SciBase Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSciBase Holding Investment Activity
SciBase Holding invested in XXX companies to date.
SciBase Holding made its latest investment on XXXXXXXX, XXXXX. SciBase Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SciBase Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SciBase Holding
| When was SciBase Holding founded? | SciBase Holding was founded in 1998. |
| Where is SciBase Holding headquartered? | SciBase Holding is headquartered in Sweden. |
| How many employees does SciBase Holding have? | As of today, SciBase Holding has over 28 employees. |
| Is SciBase Holding publicly listed? | Yes, SciBase Holding is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of SciBase Holding? | SciBase Holding trades under SCIB ticker. |
| When did SciBase Holding go public? | SciBase Holding went public in 2015. |
| Who are competitors of SciBase Holding? | SciBase Holding main competitors are RenovoRx, Sequana Medical, Baumer, Q-linea. |
| What is the current market cap of SciBase Holding? | SciBase Holding's current market cap is $46M. |
| What is the current revenue of SciBase Holding? | SciBase Holding's last 12 months revenue is $5M. |
| What is the current revenue growth of SciBase Holding? | SciBase Holding revenue growth (NTM/LTM) is 66%. |
| What is the current EV/Revenue multiple of SciBase Holding? | Current revenue multiple of SciBase Holding is 8.5x. |
| Is SciBase Holding profitable? | No, SciBase Holding is not profitable. |
| What is the current EBITDA of SciBase Holding? | SciBase Holding has negative EBITDA and is not profitable. |
| What is SciBase Holding's EBITDA margin? | SciBase Holding's last 12 months EBITDA margin is (162%). |
| What is the current EV/EBITDA multiple of SciBase Holding? | Current EBITDA multiple of SciBase Holding is (5.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.